PMID- 37757492
OWN - NLM
STAT- MEDLINE
DCOM- 20231023
LR  - 20231023
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 167
DP  - 2023 Nov
TI  - Reprogramming the lipid metabolism of dendritic cells in tumor immunomodulation 
      and immunotherapy.
PG  - 115574
LID - S0753-3322(23)01372-0 [pii]
LID - 10.1016/j.biopha.2023.115574 [doi]
AB  - Dendritic cells (DCs) are the most potent antigen-presenting cells in the human 
      body. They detect and process environmental signals and communicate with T cells 
      to bridge innate and adaptive immunity. Cell activation, function, and survival 
      are closely associated with cellular metabolism. An increasing number of studies 
      have revealed that lipid metabolism affects DC activation as well as innate and 
      acquired immune responses. Combining lipid metabolic regulation with 
      immunotherapy can strengthen the ability of antigen-presentation and T-cell 
      activation of DCs, improve the existing anti-tumor therapy, and overcome the 
      defects of DC-related therapies in the current stage, which has great potential 
      in cancer therapy. This review summarizes the lipid metabolism of DCs under 
      physiological conditions, analyzes the role of reprogramming the lipid metabolism 
      of DCs in tumor immune regulation, and discusses potential immunotherapeutic 
      strategies.
CI  - Copyright (c) 2023 The Authors. Published by Elsevier Masson SAS.. All rights 
      reserved.
FAU - Sun, Zhanbo
AU  - Sun Z
AD  - Department of Radiology, Shengjing Hospital of China Medical University, Shenyang 
      110004, China.
FAU - Zhang, Lingyun
AU  - Zhang L
AD  - Department of Medical Oncology, The First Hospital of China Medical University, 
      Shenyang 110001, China.
FAU - Liu, Lixian
AU  - Liu L
AD  - Department of Emergency Medicine, Shengjing Hospital of China Medical University, 
      Shenyang 110004, China. Electronic address: 1047882037@qq.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20230925
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
SB  - IM
MH  - Humans
MH  - *Dendritic Cells
MH  - Lipid Metabolism
MH  - Immunotherapy
MH  - Immunomodulation
MH  - *Neoplasms/metabolism
MH  - Lymphocyte Activation
OTO - NOTNLM
OT  - Dendritic cells
OT  - Immunotherapy
OT  - Lipid metabolism
OT  - Tumor immunomodulation
OT  - Tumor microenvironment
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/09/27 18:42
MHDA- 2023/10/23 01:18
CRDT- 2023/09/27 18:00
PHST- 2023/08/02 00:00 [received]
PHST- 2023/09/16 00:00 [revised]
PHST- 2023/09/21 00:00 [accepted]
PHST- 2023/10/23 01:18 [medline]
PHST- 2023/09/27 18:42 [pubmed]
PHST- 2023/09/27 18:00 [entrez]
AID - S0753-3322(23)01372-0 [pii]
AID - 10.1016/j.biopha.2023.115574 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2023 Nov;167:115574. doi: 10.1016/j.biopha.2023.115574. Epub 
      2023 Sep 25.